

Inotuzumab Ozogamicin

Poster: Braniff et al., Abstract 3338; Comparison of simulated exposure of inotuzumab ozogamicin with and without dose capping in overweight and obese patients with relapsed/refractory acute lymphoblastic leukemia ([link](#))

Poster: Castleton et al., Abstract 2369; INO-transit: Inotuzumab ozogamicin treatment prior to chimeric antigen receptor T-cell therapy in Relapsed/Refractory B-cell acute lymphoblastic leukemia: Real-world patient characteristics and outcomes in Spain, the UK and US ([link](#))

Oral: Wieduwilt et al., Abstract 444; Inotuzumab ozogamicin then blinatumomab for older adults with newly diagnosed, ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Extended follow-up of alliance for clinical trials in oncology A041703 cohort 1 reveals durable remission and survival ([link](#))

Oral: Patel et al., Abstract 441; Primary efficacy analysis of phase II study investigating tyrosine kinase inhibitor (TKI) and inotuzumab ozogamicin-based therapy for newly diagnosed Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) ([link](#))

Poster: Candoni et al., Abstract 5102; First report of the GIMEMA INO-first multicenter observational study analyzing infective and non-infective complications in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with inotuzumab ozogamicin ([link](#))

Oral: Luskin et al., Abstract 645; Venetoclax plus inotuzumab ozogamicin for relapsed and refractory ALL: Results of a phase I trial ([link](#))

Oral: Azevedo et al., Abstract 549; Predictors of survival with and without allogeneic stem cell transplantation after first salvage therapy with blinatumomab and/or inotuzumab ozogamicin for Relapsed/Refractory B-cell acute lymphoblastic leukemia ([link](#))

Oral: Jaekle et al., Abstract 329; Molecular and functional determinants of response to venetoclax and inotuzumab ozogamicin in CD22-positive ALL ([link](#))

Poster: Halder et al., Abstract 5101; Transplant outcomes of b acute lymphoblastic leukemia treated with inotuzumab ozogamicin with mini-Hyper-CVD based chemo-immunotherapy ([link](#))

Poster: Aumann et al., Abstract 3351; Inotuzumab ozogamicin in refractory or 1st or greater relapse of pediatric B-ALL as bridge to cure: A single center experience ([link](#))

Poster: Cavallaro et al., Abstract 5127; Efficacy and safety of a retreatment with inotuzumab ozogamicin in adult patients with relapsed/refractory acute lymphoblastic leukemia: A Campus ALL study ([link](#))

Poster: Akaogi et al., Abstract 1527; A combination strategy of inotuzumab ozogamicin (InO) and BCL-2 family inhibitors prevents the emergence of PGP+ ino-resistant MRD in B-cell acute lymphoblastic leukemia ([link](#))

Poster: Drucker et al., Abstract 1570; A real-world multi-institution experience of standard vs alternative dosing of inotuzumab ozogamicin for Relapsed/Refractory pediatric B-cell acute lymphoblastic leukemia ([link](#))

Poster: Wan et al., Abstract 1569; Efficacy and safety of inotuzumab ozogamicin combined with venetoclax and dexamethasone in relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) ([link](#))

Poster: Goulart et al., Abstract 5131; Long-term outcomes of a chemotherapy-free regimen of concomitant blinatumomab and inotuzumab ozogamicin in older patients with Philadelphia negative B-cell acute lymphoblastic leukemia ([link](#))

Poster: Liu et al., Abstract 3358; Safety and efficacy of low-intensity chemotherapy combined with sequential blinatumomab and inotuzumab ozogamicin immunotherapy in newly diagnosed B-ALL patients unfit/fitdeclined for intensive chemotherapy: A prospective, open-label, single-arm Phase II trial in progress ([link](#))

Poster: Goulart et al., Abstract 1567; The addition of inotuzumab ozogamicin to frontline hyper-CVAD and sequential blinatumomab leads to durable survival outcomes in adults with newly diagnosed B-cell acute lymphoblastic leukemia: Four-year follow-up of a phase 2 study ([link](#))

Poster: Ju et al., Abstract 1554; Fixed-dose inotuzumab ozogamicin combined with vincristine and prednisone regimen as induction therapy for newly diagnosed B-cell acute lymphocytic leukemia ([link](#))

Poster: Moyer et al., Abstract 3340; Outcome after relapse in older patients with Philadelphia Chromosome–Negative B-cell ALL treated with inotuzumab ozogamicin and low-dose chemotherapy in first-line therapy: A graall study ([link](#))

Inotuzumab Ozogamicin

Poster: Goulart et al., Abstract 3348; Inotuzumab ozogamicin leads to high rates of measurable residual disease negativity for patients with B-cell acute lymphoblastic leukemia in morphologic remission ([link](#))

Poster: Liu et al., Abstract 2398; Inotuzumab ozogamicin vs blinatumomab bridging optimization and second CD19 CAR-T efficacy in Relapsed/Refractory B-ALL ([link](#))

Poster: Alcalde-Mellado et al., Abstract 2324; Impact of CAR-T cells expansion and tumor burden on the outcome after inotuzumab ozogamicin as bridging therapy in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia. ([link](#))

Poster: Goulart et al., Abstract 3350; Consolidation with CAR T-cell therapy may abrogate the need for allogeneic stem cell transplant in patients with relapsed B-cell acute lymphoblastic leukemia after receiving dose-dense mini-hyper-CVD with inotuzumab ozogamicin and blinatumomab ([link](#))

Poster: Zhang et al., Abstract 4298; Selecting the optimal bridging therapy for B-ALL: A multicenter comparison of blinatumomab, inotuzumab ozogamicin, and CAR-T prior to allo-HSCT ([link](#))

Poster: Wan et al., Abstract 1569; Efficacy and safety of inotuzumab ozogamicin combined with venetoclax and dexamethasone in relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) ([link](#))

Poster: Goulart et al., Abstract 5131; Long-term outcomes of a chemotherapy-free regimen of concomitant blinatumomab and inotuzumab ozogamicin in older patients with Philadelphia negative B-cell acute lymphoblastic leukemia ([link](#))

Poster: Liu et al., Abstract 3358; Safety and efficacy of low-intensity chemotherapy combined with sequential blinatumomab and inotuzumab ozogamicin immunotherapy in newly diagnosed B-ALL patients unfit/fitdeclined for intensive chemotherapy: A prospective, open-label, single-arm Phase II trial in progress ([link](#))

Poster: Goulart et al., Abstract 1567; The addition of inotuzumab ozogamicin to frontline hyper-CVAD and sequential blinatumomab leads to durable survival outcomes in adults with newly diagnosed B-cell acute lymphoblastic leukemia: Four-year follow-up of a phase 2 study ([link](#))

Poster: Ju et al., Abstract 1554; Fixed-dose inotuzumab ozogamicin combined with vincristine and prednisone regimen as induction therapy for newly diagnosed B-cell acute lymphocytic leukemia ([link](#))

Poster: Moyer et al., Abstract 3340; Outcome after relapse in older patients with Philadelphia Chromosome–Negative B-cell ALL treated with inotuzumab ozogamicin and low-dose chemotherapy in first-line therapy: A graall study ([link](#))

Poster: Goulart et al., Abstract 3348; Inotuzumab ozogamicin leads to high rates of measurable residual disease negativity for patients with B-cell acute lymphoblastic leukemia in morphologic remission ([link](#))

Poster: Liu et al., Abstract 2398; Inotuzumab ozogamicin vs blinatumomab bridging optimization and second CD19 CAR-T efficacy in Relapsed/Refractory B-ALL ([link](#))

Poster: Alcalde-Mellado et al., Abstract 2324; Impact of CAR-T cells expansion and tumor burden on the outcome after inotuzumab ozogamicin as bridging therapy in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia. ([link](#))

Poster: Goulart et al., Abstract 3350; Consolidation with CAR T-cell therapy may abrogate the need for allogeneic stem cell transplant in patients with relapsed B-cell acute lymphoblastic leukemia after receiving dose-dense mini-hyper-CVD with inotuzumab ozogamicin and blinatumomab ([link](#))

Poster: Zhang et al., Abstract 4298; Selecting the optimal bridging therapy for B-ALL: A multicenter comparison of blinatumomab, inotuzumab ozogamicin, and CAR-T prior to allo-HSCT ([link](#))